Document Detail


Friedreich's ataxia: idebenone treatment in early stage patients.
MedLine Citation:
PMID:  12368988     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Antioxidant therapy has been applied to Friedreich's ataxia patients. We assessed the effect of idebenone treatment in patients with Friedreich's ataxia.
METHODS:
DESIGN: open-label trial. Nine Friedreich's ataxia patients (age range 11 - 19 years) were treated with idebenone (5 mg/kg/day). Patients were evaluated before the start of the therapy and throughout one year of treatment by International Cooperative Ataxia Rating Scales (ICARS) scores, neurophysiological investigations and echocardiographic measurements. Serum idebenone concentrations were measured by HPLC with electrochemical detection. The number of GAA repeats at the frataxin gene was analyzed by PCR.
RESULTS: Serum idebenone concentrations ranged between 0.04 - 0.37 micro mol/L. Significantly positive correlation was observed between idebenone values and the percentage of difference between the ICARS scores before and 12 months after the start of the therapy (r = 0.883; p = 0.002). Significant reduction was observed comparing the ICARS scores in baseline conditions and after 3 months of treatment (p = 0.017). No differences were observed in echocardiographic measurements after the start of the therapy.
CONCLUSIONS: Cerebellar improvement was notable in mild patients after the first 3 months of therapy. Idebenone treatment at early stages of the disease seems to reduce the progression of cerebellar manifestations. Further blind trials with a greater number of patients and higher doses are needed to fully assess the therapeutic potential of idebenone in Friedreich's ataxia.
Authors:
R Artuch; A Aracil; A Mas; C Colomé; M Rissech; E Monrós; M Pineda
Related Documents :
21756048 - Ultrasound-guided percutaneous microwave ablation for symptomatic uterine fibroid treat...
22008088 - Comparison of standard fusion with a "topping off" system in lumbar spine surgery: a pr...
21928258 - Triple therapy for corneal neovascularization: a case report.
25318098 - Bilateral stenting methods for hilar biliary obstructions.
2347078 - Porcine collagen corneal shield treatment of persistent epithelial defects following pe...
8970468 - Should we embrace new drugs with open arms? experience from a community-based, open-arm...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neuropediatrics     Volume:  33     ISSN:  0174-304X     ISO Abbreviation:  Neuropediatrics     Publication Date:  2002 Aug 
Date Detail:
Created Date:  2002-10-07     Completed Date:  2002-11-13     Revised Date:  2014-07-28    
Medline Journal Info:
Nlm Unique ID:  8101187     Medline TA:  Neuropediatrics     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  190-3     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Antioxidants / therapeutic use*
Benzoquinones / therapeutic use*
Cerebellum / drug effects,  physiopathology,  ultrasonography
Child
Echocardiography
Female
Follow-Up Studies
Friedreich Ataxia / drug therapy*,  physiopathology,  ultrasonography
Humans
Male
Recovery of Function / physiology
Time Factors
Ubiquinone / analogs & derivatives
Chemical
Reg. No./Substance:
0/Antioxidants; 0/Benzoquinones; 1339-63-5/Ubiquinone; HB6PN45W4J/idebenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Screening for adenylosuccinate lyase deficiency: clinical, biochemical and molecular findings in fou...
Next Document:  Infantile Alexander disease: a GFAP mutation in monozygotic twins and novel mutations in two other p...